Dr. Shaal Patel, a board certified physician in hematology, oncology, and internal medicine, spoke with Healthline about how myelodysplastic syndromes (MDS) can benefit from supportive therapy, ...
Presentation of the COMMANDS trial offered practice-changing results for luspatercept. COMMANDS: Luspatercept Boosts Population With Lower-Risk Myelodysplastic Syndromes Who Are Freed From Blood ...
Results show that it may be beneficial to add longitudinal monitoring of kidney function to the management of patients with MDS.
MDS can cause a significant lack of energy that reduces your quality of life. These tips can help you better manage MDS fatigue. Myelodysplastic syndromes (MDS) is a type of cancer that shows up as a ...
The prognostic impact of monocytosis in patients with myelodysplastic syndromes (MDS) is not well-studied and not been clearly defined. Patients with MDS and monocytosis had a shorter overall survival ...
An August approval of luspatercept, sold as Reblozyl, which promises to alleviate transfusion burdens for patients with lower-risk MDS, was among the news items that drew readers’ attention. Articles ...
Successful Management of Neutropenic Sepsis Is Key to Better Survival of Patients With Blood Cancer in Sri Lanka: Real-World Data From the Resource-Limited Setting Myelodysplastic syndromes (MDS) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results